Risk factors for fragility fractures in patients with immunobullous diseases on long-term systemic glucocorticoids
https://doi.org/10.4081/dr.2024.9813
HTML: 0
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Dear Editor, Systemic glucocorticoids remain a cornerstone of therapy in immunobullous diseases. Yet little is known about glucocorticoid-induced osteoporosis (GIOP) in patients with immunobullous diseases. We performed a retrospective review of medical records at an immunodermatology clinic in a Singaporean tertiary centre. Inclusion criteria consisted of patients with a newly diagnosed immunobullous condition between January 2011 and October 2017 who were on long-term (>= 3 months) systemic glucocorticoids at a minimum daily dose of prednisolone 15mg. [...]
Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews. 1998.
Allen CS, Yeung JHS, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database of Systematic Reviews 2016, Issue 10.
Tee SI, Yosipovitch G, Chan YC, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Archives of dermatology. 2012;148:307-14.
Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis & rheumatology 2017;69:1521-37.
Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. 2016;31:16-35.
Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. Journal of Bone and Mineral Research. 2013;28:1729-37.
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
